Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer

Jonathan Ledermann, Philipp Harter, Charles Gourley, Michael Friedlander, Ignace Vergote, Gordon Rustin, Clare Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra, Daniela Matei, Euan Macpherson, Claire Watkins, James Carmichael, Ursula Matulonis

Research output: Contribution to journalArticlepeer-review

Abstract

Olaparib (AZD2281) is an oral poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitor that has shown antitumor activity in patients with high-grade serous ovarian cancer with or without BRCA1 or BRCA2 germline mutations.
Original languageEnglish
Pages (from-to)1382-92
Number of pages11
JournalNew England Journal of Medicine
Volume366
Issue number15
DOIs
Publication statusPublished - 2012

Fingerprint

Dive into the research topics of 'Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer'. Together they form a unique fingerprint.

Cite this